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Abstract
Malaria caused by Plasmodium falciparum is a catastrophic disease worldwide (880,000 deaths 
yearly). Vaccine development has proved difficult and resistance has emerged for most 
antimalarials. In order to discover new antimalarial chemotypes, we have employed a phenotypic 
forward chemical genetic approach to assay 309,474 chemicals. Here we disclose structures and 
biological activity of the entire library, many of which exhibited potent in vitro activity against 
drug resistant strains, and detailed profiling of 172 representative candidates. A reverse chemical 
genetic study identified 19 new inhibitors of 4 validated drug targets and 15 novel binders among 
61 malarial proteins. Phylochemogenetic profiling in multiple organisms revealed similarities 
between Toxoplasma gondii and mammalian cell lines and dissimilarities between P. falciparum 
and related protozoans. One exemplar compound displayed efficacy in a murine model. Overall, 
our findings provide the scientific community with new starting points for malaria drug discovery.
The wide-spread resistance of P. falciparum to many antimalarial drugs, the dependence of 
all new combinations on artemisinins (for which resistance may have emerged),1 ,2 and new 
efforts to eradicate malaria all drive the need to develop new, effective, and affordable 
antimalarial drugs.3 Although our understanding of the parasite’s biology has increased with 
sequencing of the genome4 and the development of new technologies to study resistance 
acquisition,5 ,6 ,7 few new drug targets or classes of drugs have been clinically validated.8 
The lack of publicly-accessible antimalarial chemotypes with differing modes of action has 
significantly hindered efforts to discover and develop new drugs.9 In order to address this 
urgent need, we have developed a forward chemical genetic approach to identify novel 
antimalarials (Supplementary Fig. 1).
The forward chemical genetic screen
A library containing 309,474 unique compounds, designed at the scaffold level to provide 
diverse, comprehensive coverage of bioactive space,10 ,11 was screened against 
Plasmodium falciparum (Pf3D7) at a fixed concentration of 7 μM (Supplementary 
Information).12 Fidelity of the assay was examined by receiver operator characteristic 
(ROC) analysis and other metrics (Supplementary Fig. 2 and 3), demonstrating good 
discriminatory power (AUC ~0.85) and suggesting that a cutoff of ≥ 80% activity would 
retain the majority of true positives. The strength of the assay was further determined by 
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testing a set of bioactive compounds including known antimalarials, all of which were re-
identified (Supplementary Table 3), demonstrating that the method was very likely to 
identify any molecule acting by a known mechanism. The primary screen gave 1152 
compounds with activity > 80%. These 1152 compounds and the true positives from the 
ROC set were serially diluted and tested against both the chloroquine-sensitive Pf3D7 and 
the chloroquine-resistant PfK1 strain, giving 1300 validated hits that had saturated dose-
response curves. Chemical structure analysis of validated hits by topology mapping and 
clustering10 revealed a wide distribution of chemotypes in the active chemical space, with 
several displaying promising structure-activity relationships (Fig. 1). While all known 
antimalarial scaffolds (aminoquinolines, quinolones, bis-amidines) present in the screening 
collection were identified, providing positive controls for the screen, most of the 
chemotypes identified were novel. 561 of the validated hits had EC50 values ≤ 2 μM against 
either Pf3D7 or PfK1 and a therapeutic window ≥ 10-fold against two mammalian cell lines 
(HepG2 & BJ). From this set, 228 structurally distinct, pure compounds were re-purchased. 
Antimalarial potencies of ~75% of these compounds (172) were re-confirmed to within 10-
fold (Bland-Altman analysis, Supplementary Fig. 4) by three laboratories using distinct 
methods providing the cross-validated hit set utilized for all subsequent experiments.
Combination with antimalarial drugs
Due to rapid resistance acquisition, the WHO recommends combination therapy.13 The 
agonistic and antagonistic synergies of the cross-validated set were therefore quantified by 
measuring EC50 shifts in the presence of a fixed fraction of potency (EC10) concentration of 
chloroquine, mefloquine, artemisinin, and atovaquone. Most cross-validated compounds 
were additive in effect or had minor synergies with existing drugs. Two classes 
demonstrated strong synergies (EC50′s reduced by ≥ 10-fold): the diaminonaphthoquinones 
with artemisinin, and the dihydropyridines with mefloquine (Fig. 2). One 
diaminonaphthoquinone and a cycloguanil analog displayed antagonism with chloroquine 
and mefloquine, respectively.
Reverse chemical genetics
The advantages of phenotypic screens for the identification of novel chemotypes are that no 
a priori assumptions are made concerning drug targets and that active compounds inherently 
have cellular bioavailability. Because insight into mechanism of action is helpful for drug 
development, we also investigated the interaction of the cross-validated set with 66 potential 
targets using enzyme inhibition assays and thermal-melt shift assays (to detect binding).
Three high-priority, well characterized biological targets were evaluated in activity assays 
(Fig. 3, left): P. falciparum dihydroorotate dehydrogenase (PfDHOD), hemozoin formation, 
and falcipain-2 (PfFP-2). PfDHOD, catalyzes the oxidation of dihydroorotate to orotate in 
de novo pyrimidine biosynthesis, which is essential for parasite viability.14 ,15 Three 
compounds inhibited this enzyme: two triazolopyrimidines, structurally related to known 
PfDHOD inhibitors with comparable potencies,14 and a dihydropyridine, structurally related 
to the calcium blocker felodipine. The potency of these compounds against PfDHOD 
strongly correlated with their antimalarial activities (Supplementary Table 5). Furthermore, 
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these compounds were inactive against transgenic parasites expressing Saccharomyces 
cerevisiae dihydroorotate dehydrogenase (Supplementary Table 6). Next, hemozoin 
formation inhibition was investigated. The parasite digests host hemoglobin to provide 
amino acids, detoxifying the resulting heme molecules by conversion to a crystallized form 
known as hemozoin. Heme detoxification is believed to be the target of many antimalarial 
drugs.16 Twelve compounds exhibited appreciable efficacy in an in vitro hemozoin 
formation assay,17 including analogs of quinazoline, benzofuran, benzimidazole, and 
carbazole as well as amodiaquine, a known hemozoin formation inhibitor present in our 
library. The correlation between enzyme inhibitory potency and antimalarial potency was 
similar to that displayed by the positive controls quinine and amodiaquine (Supplementary 
Table 5). The third enzyme assayed was PfFP-2, which plays a critical role in hemoglobin 
degradation.18 Falcipains are redundant in P. falciparum, with four known homologs 
including two (falcipain-2 and falcipain-3) that appear to play key roles in erythrocytic stage 
parasites.19 Three weakly FP-2 inhibitors were identified. Thus 19 compounds (11%) were 
inhibitors of validated antimalarial targets.
To expand the pool of potential targets, the compounds were tested for binding to 61 
recombinant malarial proteins (95% purity or better after affinity and size exclusion 
chromatography, Supplementary Table 1) in a thermal-melt shift assay.20 Fifteen 
compounds displayed reproducible thermal shifts with seven malarial proteins (Fig. 3, right; 
Kd’s in Supplementary Table 2): 6-phosphogluconolactonase, 6-pyruvoyltetrahydropterin 
synthase, choline kinase, D-ribulose-5-phosphate 3-epimerase, dUTPase, glycogen synthase 
kinase 3, and thioredoxin. 2 compounds bound multiple proteins. 2 out of the 7 proteins are 
in essential malarial pathways: phosphatidylcholine synthesis21 (choline kinase) and redox 
metabolism22 (thioredoxin). The remaining 5 protein targets potentially represent novel 
antimalarial drug targets.
The potential for cross resistance
To evaluate the potential for cross-resistance with existing drugs, the cross-validated 
compounds were tested against a panel of P. falciparum strains with different 
chemosensitivities to known antimalarials, including Pf3D7 (chloroquine sensitive), PfK1, 
PfW2, PfV1/S and PfDd2 (all resistant to both chloroquine and to antifolates), PfSB-A6 and 
PfD10_yDHOD (both chloroquine sensitive and atovaquone resistant). All strains were 
profiled for sensitivity to a set of antimalarial drugs to normalize activity (Supplementary 
Table 3). 58 cross-validated compounds displayed similar potencies (EC50 shift ≤ 3-fold) 
against Pf3D7, PfK1, PfV1/S and PfSB-A6, suggesting that these compounds do not share 
mechanisms of resistance with chloroquine, atovaquone, or sulfadoxine/pyrimethamine. A 
subset of the 172 compounds that were inactive against drug resistant P. falciparum strains 
with known mutations in target proteins were tested against Pf3D7 dihydrofolate reductase 
and P. yoelii cytochrome bc1 complex in biochemical assays. Two inhibitors were identified 
for each protein (Supplementary Table 5 and 6).
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To understand relationships between chemical sensitivity of Plasmodium and related 
parasites, the cross-validated set was tested against three additional protozoan parasite 
species: Toxoplasma gondii (Tg), which belongs to the same phylum as Plasmodium 
(Apicomplexa); Leishmania major (Lm) and Trypanosoma brucei (Tb), which are both 
Kinetoplastida, unrelated to the Apicomplexa; and an expanded panel of human cell lines 
including a Burkitt’s lymphoma line (Raji) and embryonic kidney fibroblast cells 
(HEK-293). Phylogenetic criteria predict that chemical sensitivity should correlate with 
evolutionary history, due to homology between key protein targets, as is known to be the 
case for many antiparasitic drugs.23 ,24 Although a few compounds showed activity in other 
parasites, most were highly selective for Plasmodium (Fig. 4), while Toxoplasma exhibited a 
chemosensitivity pattern more similar to human cell lines. Similarly, the highly potent anti-
leishmanial benzothiazoles were only weakly active against the related Trypanosoma. These 
findings suggest that chemical sensitivity of pathogens is regulated by a combination of 
pathogen genetics, physiology, and relationships to host and vector species in vivo.
Early leads for drug development
In order to understand the potential for development of the novel chemotypes, the 
pharmacokinetic properties of the cross-validated set were assessed. The majority are 
reasonably drug-like, with 78% of compounds have no violations of the Lipinski Rule of 5, 
and 99% have one or fewer violations.25 Within the cross-validated set were embedded 3 
chemical series that had multiple members that together gave structure-activity relationships 
that spanned 1000-fold potency differences, had consistent activity in drug resistant strains, 
had very good cellular therapeutic windows, and had at least one member with an EC50 
more potent than 50 nM. An exemplar compound was selected from each series and fully 
profiled using standard models of in vitro and in vivo adsorption, distribution, metabolism, 
and toxicity (Supplementary Table 7). Each possessed reasonable characteristics for 
developable hits, indeed each comes close to passing MMV criteria for “late leads.” The 
compound from these exemplars with the best pharmacokinetic profile, was further 
evaluated to measure in vivo antimalarial activity and displayed efficacy in a murine malaria 
model infected with P. yoelii. A twice-daily administration of 100 mg/kg for 3 days resulted 
in a 90% suppression of the parasitemia (Supplementary Fig. 5). Although it is not 
suggested that any of the compounds discussed herein are bone fide preclinical candidates 
all provide reasonable starting points for drug development.
Conclusions
Drug therapy remains a key component in controlling malaria. Current challenges of rapid 
acquisition of resistance, cross-resistance, and dependence upon a limited number of 
chemical classes of antimalarials highlight the need to enhance our understanding of the 
“chemical space” that can fruitfully be brought to bear on malaria treatment. Solving this 
problem requires understanding the relationships between the structures of compounds 
active against malaria parasites and their potency, selectivity, and targets. We have 
identified a number of novel compounds and defined these relationships. We expect that 
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these findings will provide novel paths for drug development and hope that making this set 
of well characterized, non-proprietary lead antimalarials publicly available to the global 
research community will help to reinvigorate drug discovery for malaria.
Methods summary
The primary screen was carried out by comparing quantities of DNA in treated and control 
cultures of Plasmodium falciparum in human erythrocytes after 72 h incubation with a fixed 
concentration of 7 μM of the test compounds.. The secondary potency determination was 
made by using the same assay in a dose-response mode with 12 concentrations varying from 
10 μM to 5 nM. Chemical sensitivities of the human cell lines and T. brucei were 
determined by measuring their ATP content (Cell Titer Glo, Promega). T. gondii parasites 
expressing luciferase were cultured and drug sensitivity was determined by luminescence; L. 
major promastigotes drug susceptibility (Alamar Blue assay, Promega). Chemicals were 
assayed for hemozoin formation inhibition17, PfDHOD15, FP-227 activities based on 
previously described methods. Thermal shift assays were done at compound concentrations 
of 25 μM and protein concentrations of 100 μg/ml. All data processing and visualization, 
and chemical similarity and substructure analysis was performed using custom programs 
written in the Pipeline Pilot platform (Accelrys, v.7.0.1) and the R program.26 A complete 
description of the methods can be found in Supplementary Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Chemical structure network graph and antimalarial potencies of the 1300 validated 
hits
Topologically similar molecules cluster together in the branches of the network. To 
construct the graph, molecules were first abstracted to scaffolds and then further to cores 
using the Murcko algorithm.10 Each of these structural entities is represented as a node, and 
nodes are connected via edges according to topological relationships. Molecular nodes are 
coded to reflect potency against PfK1 (low = white, high = blue) and Pf3D7 (low = small, 
high = large). The highly branched structure of the full network graph (bottom half of the 
figure) indicates that the 1300 compounds are organized into clusters of clusters: cores are 
well sampled by multiple scaffolds, and the cores themselves are grouped into families of 
related chemotypes. Previously reported antimalarial compounds are highlighted. The top 
half of the figure provides greater detail on three potent chemotypes with well-developed 
structure activity relationships: (A) tetrahydroisoquinoline, (B) naphthoquinone, and (C) 
dihydropyridine. Data in supplementary file (‘Guiguemde_Excel_SI’, ‘Structure’ tab).
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Figure 2. Reduced representation of the network map showing synergistic activities with 
clinically relevant antimalarials
The size of the nodes reflect the magnitude of the logarithmic difference between EC50 in 
the presence and absence of EC10 of exemplar antimalarial drugs. Absolute differences less 
than one log unit were not considered significant. Synergistic and antagonistic compounds 
are uniformly color-coded blue and red, respectively. Highly synergistic compounds can be 
seen with artemisinin and mefloquine. Data in supplementary file (‘Guiguemde_Excel_SI’, 
‘Synergy’ tab).
Guiguemde et al. Page 10









Figure 3. Reduced representation of the network map showing the interaction of the cross-
validated hits with potential biological targets
The network map on the left displays compounds targeting well validated protein targets as 
measured in inhibition assays (EC50 ≤ 15 μM). The map on the right shows compounds that 
bind to purified malarial proteins according to thermal-melt shift experiments. The size of 
nodes representing active or binding compounds is increased for clarity. Note that few of the 
compounds discovered in this study are potent inhibitors of known targets or bind potently 
to putative targets. Data in supplementary file (‘Guiguemde_Excel_SI ’, ‘Sensitivity’ tab).
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Figure 4. Phylochemogenetic profiling
Phylochemogenetic analysis of the cross-validated compounds using a two-way hierarchical 
clustering. of growth inhibition against P. falciparum strains (Pf3D7, PfK1, PfV1/S), other 
eukaryotic parasites (Toxoplasma gondii [Tg], Trypanosoma brucei [Tb], Leishmania major 
[Lm]), and human cell lines (HEK293, BJ, Raji, and HepG2). Columns represent single 
compounds and are clustered according to potency against the cell lines and organisms. 
Neighboring compounds share a similar potency spectrum. Rows represent a single cell line 
or organism and are clustered according to their chemosensitivity to the compounds in the 
study. A phylogenetic tree of the organisms in this study is provided for reference. Note that 
despite the many known examples of taxonomically-conserved pathways, on a global level, 
phylogeny is a poor predictor of chemical sensitivity profiles: Toxoplasma responses more 
closely parallel human than their evolutionary siblings, Plasmodium. Data in supplementary 
file (‘Guiguemde_Excel_SI’, ‘Phylo’ tab).
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